Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
General Montana
Archived
•
November 5, 2026
•
Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



